Indication name: Acromegaly
Acromegaly – Market outlook,
Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030
(Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan
& China).
Acromegaly is a
disorder that occurs when your body makes too much growth hormone (GH).
Produced mainly in the pituitary gland, GH controls the physical growth of the
body. Acromegaly may also cause thickening of the soft tissues of the body,
including the heart, lips, and tongue. When the disease affects children prior
to the end of puberty, excess growth hormone can lead to accelerated growth and
tall stature, known as gigantism. Acromegaly may be caused by the ineffective
control of growth hormone-secreting cells by the hypothalamus (a gland in the
brain that regulates hormone secretions).
In rare cases, non-pituitary
tumors in the pancreas, lungs or adrenal glands may cause acromegaly. In some
cases, acromegaly may occur as part of certain genetic syndromes including
multiple endocrine neoplasia type 1, familial isolated pituitary adenoma, the
Carney complex and McCune-Albright syndrome. X-linked acrogigantism causes
gigantism and is due to microduplications of segments of the X chromosome.
Epidemiology-
About 3 to 14 of every 100,000 people have been diagnosed as having acromegaly.
Competitive landscape of Acromegaly includes country specific approved as well
as pipeline therapies. Any asset/ product specific designation or review and
Accelerated Approval are being tracked and supplemented with analyst
commentary.
KOLs
insights of Acromegaly 8 MM market from center of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm and Unmet needs.
Acromegaly market forecast: Patient Based Forecast Model (MS. Excel Based
Automated Dashboard) which Data Inputs with sourcing, Market Event and Product
Event, Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden and pricing scenario,
Summary and Insights.
S. No Asset Company Stage
1 Sandostatin Novartis AG Approved (Generic Competition)
2 Sandostatin LAR Novartis AG Approved
3 Signifor Recordati SpA Approved
4 Somatuline Autogel Ipsen SA Approved
5 Somavert Nektar Therapeutics Approved
6 CAM2029 Novartis AG III
7 Mycapssa Chiasma, Inc III
8 ATL1103 Antisense Therapeutics, Ltd. II
9 COR-005 Strongbridge Biopharma plc II
10 CRN00808 Crinetics Pharmaceuticals, Inc. II
11 IONIS-GHR-LRx Ionis Pharmaceuticals, Inc. II
12 DP1038 Dauntless Pharmaceuticals, Inc. I
13 Glide Octreotide Enesi Pharma Limited I
14 ONO-5788 Ono Pharmaceutical Company, Ltd. I
15 Q-Octreotide Midatech Pharma PLC I
16 ITF-2984 Italfarmaco S.p.A. Development Outside U.S.
17 AP102 Amryt Pharma plc Preclinical
18 AQST-305 Aquestive Therapeutics, Inc Preclinical
No comments:
Post a Comment